Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... Calif. (PRWEB) , ... July 18, 2019 , ... ... clinical, regulatory and manufacturing experience. As a result of a two-year research ... commercialize the Calidi oncolytic virus platform in veterinary medicine. VetStem should be able ...
(Date:7/17/2019)... , ... July 16, 2019 , ... At nearly eleven ... back legs. According to his owner, in the last year or so, he ... him. His veterinarian, Dr. Cindy Echevarria of VCA University Animal Hospital ...
(Date:7/9/2019)... ... July 08, 2019 , ... KMK Consulting, ... of Cambridge, MA. This expansion strengthens KMK’s presence for the sales, support, and ... sales force effectiveness consulting for the biotechnology corridor. With this expansion, KMK ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... POWAY, Calif. (PRWEB) , ... June 18, 2019 , ... ... submitted an Investigational New Drug (IND) application to the FDA for use of a ... stem cells as a treatment of osteoarthritis in the knee. This IND is ...
(Date:6/11/2019)... BETHESDA, Md. and ROANOKE, Va. (PRWEB) , ... ... ... virtual care optimized for microlearning engagement, and Carilion Clinic, a national leader in ... leveraging the latest in virtual care. , Mytonomy recently deployed its ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... from the USPTO providing proprietary interest to our methodology, processes, and diagnostic ... DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring ...
(Date:5/21/2019)... Ethiopia (PRWEB) , ... May 21, 2019 , ... ... Brauerei in Berlin (VLB) today officially opened the inaugural Africa Brewing Conference dedicated ... and malting industry in Africa. The event, which is supported through a partnership ...
Breaking Biology Technology: